Chinese Academy of Sciences

Hong Kong Baptist University

Wigen Biomedicine Technology (shanghai) Co., Ltd.

Fudan University

Cisen Pharmaceutical Co., Ltd.

Nanjing Pailexing Pharmaceutical Technology Ltd.

Shanghai University of Traditional Chinese

Kingsound & Partner

Shanghai Lead Discovery Pharmaceuticals Limited Company

Jiangsu Kanion Pharmaceutical Co., Ltd.

Kaixian Chen

Hualiang Jiang

Hong Tao Liu

Jiang Wang

Jian Li

Jia Tao Li

Jingya Li

Mingbo Su

Xiaomin Luo

Zhaoxiang Bian

Aiping Lu

Xin Xie

Hongxi Xu

Jing Lan Chen

Jian Wang

Yu Chen Zhou

Jing Li

Zeng Li

Cheng Luo

Ying Chen

Yuanyuan Zhang

Dajian Yang

Shilin Chen

Haifeng Sun

Shuni Wang

Shengbin Zhou

Liyan Yue

Wei Wan

Wei Zhu

Jun Wei Zhang

Fei Zhao

Dong Zhang

Yuli Xie

Xu Han

Yubo Zhou

Albert Sun Chi Chan

Hong Jie Zhang

Zhiyi Yao

Xuechu Zhen

Liyuan Zhu

Yuanzhi Lao

Xiaoyu Wang

Hao Shen

Panfeng Peng

Chunpu Li

Wei Tang

Hui Li

Bo Li

Hui Chen

Fei Ye

Lu Lu

Dan Li

Jingkang Shen

Jing Zhao

Tao Sun

Yan Fu

Jianping Zuo

Chengyuan Lin

Jianhua Shen

Lei Tang

Peng Sun

Haiyan Zhang

Bing Zhou

Yushe Yang

Yiping Wang

Yongtang Zheng

Liumeng Yang

Chenglin Wu

Xu Shen

Xican Tang

Bing Xiong

Xin Li

Yi Zang

Weijuan Kan

Weiliang Zhu

Zhijian Xu

Heng Li

Fenghua Zhu

Shibo Jiang

Lili Chen

Sun Chi Albert Chan

Tiantian Chen

Donglu Bai

Yiming Yang

Jingjing Peng

Haibin Luo

Hong Liu

Yu Zhou

Dandan Sun

Haonan Zhang

Yue Lv

Wenwei Fu

Wangke Qian

Leiping Yu

Heyao Wang

Wenxian Cai

Hongsheng Tan

A ketoamide compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically, the ketoamide compound shown in formula (A), a racemate, an enantiomer, or a diastereoisomer thereof, or any mixture of same, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The ketoamide compound can effectively inhibit coronavirus or Ebola virus, and thereby implement the prevention or treatment of diseases related to coronavirus or diseases related to Ebola virus.

Ketoamide compound and preparation method, pharmaceutical composition, and use thereof

Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibitory effect on phosphodiesterase (PDE4), and can be used in the prevention, treatment or auxiliary treatment of multiple diseases associated with the activity or expression of phosphodiesterase, especially PDE4-associated immune and inflammatory diseases, such as psoriasis and arthritis.

Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof

The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.

Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof

Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

Pharmaceutical use of thiophene [3,2-d] pyrimidine-4-ketone compound

The present invention relates to use of an aminomethylenecyclohexane-1,3-dione compound, more particularly to use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in preparing a drug for regulating or treating a disease related to autophagy, especially mammalian ATG8 homologous proteins. 

Use of aminomethylenecyclohexane-1,3-dione compound

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. 

Compound used as autophagy regulator, and preparation method therefor and uses thereof

The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator. 

Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof

Disclosed is a(Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.

extract, preparation method for same, and use thereof in sugar reduction, weight loss, and lipid reduction

The present invention relates to phenyl [a]indole[2,3-g]quinolizine compounds represented by formula (I), a preparation method therefor, a pharmaceutical composition, and applications thereof. Specific applications are applications in the preparation of drugs for treating diseases related to a proprotein convertase subtilisin Kexin-9 (PCSK9), comprising the applications in the preparation of drugs for treating hyperlipemia, hypercholesterolemia, hypertriglyceridemia, fatty liver deformation, atherosclerosis, obesity and other metabolic diseases. 

Phenyl [a]indole[2,3-g]quinolizine compounds, preparation method therefor, pharmaceutical composition, and applications thereof

Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw material, (S)-&#x3b2;-amino acid is obtained by asymmetric resolution induced by using a nickel chelate, and Maraviroc is synthesized by using (S)-3-amino-3-phenylpropionic acid as a key intermediate with a high yield and the ee value reaching 98.2% or more. The method of the present invention has widely available materials, mild synthetic process conditions, is easy to control, and produces a product of a high optical purity.

Method for synthesizing novel chiral ligand, metal chelate, a variety of non-natural amino acids, maraviroc and key intermediate thereof

Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers. 

Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof

A fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof are described. The triazolopyridine can be used as a positive allosteric modulator of an mGluR2, and is highly selective in activating the mGluR2, exerting no activation or very limited activation of other homologous metabotropic glutamate receptor. The triazolopyridine can thus be used to prepare a product for treating an mGluR2-related disease, such as a central nervous system disease or neurological disease. 

Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof

The invention describes a polymorph of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid maleate and a preparation method therefor. The polymorph is a crystal having high stability and low hygroscopicity, and the crystal form is selected from crystal form A, crystal form B and crystal form C. Furthermore, the crystal form has a strong in-vivo hypoglycemic activity and can be used for the preparation of a novel drug for the treatment or prevention of diabetes mellitus type H and/or complications of diabetes mellitus type H.

Polymorph of DPPIV inhibitor maleate and preparation method therefor

Compounds of formula I are provided. Also provided are methods of preparing the compounds of formula (I), and methods of using the compounds of formula (I) as a negative allosteric modulator of a metabotropic glutamate receptor (mGluR) subtype 5. 

5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof

The invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a pharmaceutical composition of the formula I compound salt form. The salt form of the invention provides powerful in vivo hypoglycemic activity and is expected to be a novel pharmaceutical active ingredient for treating or preventing diabetes mellitus type 2 and/or complications of diabetes mellitus type 2 

Salt form of DPPIV inhibitor and preparation method thereof

Growing community of inventors

Shanghai, China

Kaixian Chen